Skip to content

A randomized double-blind controlled clinical study of Qiangxin compound in the treatment of type 2 cardiorenal syndrome under the hierarchical management mode of Integrated Chinese and Western Medicine

A randomized double-blind controlled clinical study of Qiangxin compound in the treatment of type 2 cardiorenal syndrome under the hierarchical management mode of Integrated Chinese and Western Medicine

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003812
Enrollment
Unknown
Registered
2020-08-28
Start date
2020-11-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 cardiorenal syndrome

Interventions

Sponsors

Traditional Chinese Medicine Hospital of Shanghai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Heart failure stage C, D, heart function II to III with mild to severe renal insufficiency.

Exclusion criteria

Exclusion criteria: 1. Patients with renal insufficiency caused by non cardiac causes; 2. Pregnant or lactating women, allergic constitution and allergic to a variety of drugs; 3. Combined with severe liver insufficiency and endocrine system, hematopoietic system and other serious primary diseases; 4. Those with mental disorder and unwilling to cooperate; 5. The factors that can increase the mortality rate include cardiogenic shock, severe ventricular arrhythmia, complete atrioventricular block and obvious infection; 6. Creatinine clearance rate < 15% of patients requiring dialysis; 7. History of cardiac surgery.

Design outcomes

Primary

MeasureTime frame
Minnesota Heart Failure Quality of life questionnaire;6-minute walk test;Heart failure symptom rating scale;

Secondary

MeasureTime frame
Alanine aminotransferase;Serum creatinine;total bilirubin;Cystatin C;Aspartate aminotransferase;Urinary microprotein;brain natriuretic peptide;

Countries

China

Contacts

Public ContactMiao Zhou

Traditional Chinese Medicine Hospital of Shanghai

569257706@qq.com+86 13472693616

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026